[{"notes_id":"1_2082","category":"5","subcategory":"1","title":"Trimethoprim","body":"Trimethoprim is an antibiotic, mainly used in the management of urinary tract infections.<br \/><br \/>Mechanism of action<br \/><ul><li><span class=\"concept\" data-cid=\"6381\">interferes with DNA synthesis by inhibiting dihydrofolate reductase<\/span><ul><li>may, therefore, <span class=\"concept\" data-cid=\"3132\">interact with methotrexate<\/span>, which also inhibits dihydrofolate reductase<\/li><\/ul><\/li><\/ul><br \/>Adverse effects<br \/><ul><li><span class=\"concept\" data-cid=\"10296\">myelosuppression<\/span><\/li><li><span class=\"concept\" data-cid=\"8792\">rise in creatinine<\/span><ul><li>trimethoprim inhibits tubular secretion of creatinine in the proximal tubule.<\/li><li>this is a pharmacological effect on renal handling of creatinine, not true renal injury.<\/li><li>because creatinine clearance is reduced (without GFR actually falling), the serum creatinine rises<\/li><li>the rise in creatinine is typically 10\u201330% above baseline and occurs rapidly after starting trimethoprim<\/li><li>it does not reflect a genuine decline in glomerular filtration rate (GFR)<\/li><li>trimethoprim blocks the ENaC channel in the distal nephron, causing a <span class=\"concept\" data-cid=\"2297\">hyperkalaemic<\/span> distal RTA (type 4)<\/li><\/ul><\/li><\/ul><br \/>Use in pregnancy<br \/><ul><li>the BNF advises that there is a: '<i><span class=\"concept\" data-cid=\"5062\">Teratogenic risk in first trimester (folate antagonist)<\/span>. Manufacturers advise avoid during pregnancy.<\/i>'<\/li><\/ul>","notes_hash":"90b11b56999ed539f85a2c8871206ea7","knowledge_graph_node_id_link":10847,"links":"","media":"","concepts_for_notes":{"3132":{"concept_text":"Trimethoprim and co-trimoxazole should be avoided in patients on methotrexate","concept_percentile":"81"}},"category_name":"Infectious disease \/ Haematology \/ Immunology","subcategory_name":"Infectious disease","comment_count":1},"",[]]